Robert B. Jenkins, M.D., Ph.D. - Publications

Affiliations: 
Laboratory Medicine and Pathology Mayo Clinic, Rochester, MN, United States 
Area:
chromosome 19 q-arm and 8 q-arm, gene cloning
Website:
http://www.mayo.edu/research/faculty/jenkins-robert-b-m-d-ph-d/BIO-00077489

146 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, von Deimling A, Weller M. cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathologica. PMID 30259105 DOI: 10.1007/s00401-018-1913-0  0.32
2017 Holdhoff M, Cairncross GJ, Kollmeyer TM, Zhang M, Zhang P, Mehta MP, Werner-Wasik M, Souhami L, Bahary JP, Kwok Y, Hartford AC, Chakravarti A, Yegnasubramanian S, Vogelstein B, Papadopoulos N, ... ... Jenkins RB, et al. Genetic landscape of extreme responders with anaplastic oligodendroglioma. Oncotarget. PMID 28388591 DOI: 10.18632/oncotarget.16773  0.32
2016 Yoon HH, Lewis MA, Foster NR, Sukov WR, Khan M, Sattler CA, Wiktor AE, Wu TT, Jenkins RB, Sinicrope FA. Central nervous system relapse in patients with untreated her2-positive esophageal or gastroesophageal junction adenocarcinoma. International Journal of Cancer. PMID 27198655 DOI: 10.1002/ijc.30200  0.32
2016 Guo R, Wang X, Chou MM, Yan A, Wenger DE, Al-Ibraheemi A, Molavi DW, Aboulafia A, Jin L, Fritchie K, Oliveira JL, Jenkins RB, Westendorf JJ, Dong J, Oliveira AM. PPP6R3-USP6 Amplification: Novel Oncogenic Mechanism in Malignant Nodular Fasciitis. Genes, Chromosomes & Cancer. PMID 27113271 DOI: 10.1002/gcc.22366  0.32
2016 Trock BJ, Fedor H, Gurel B, Jenkins RB, Knudsen BS, Fine SW, Said JW, Carter HB, Lotan TL, De Marzo AM. PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 27080984 DOI: 10.1038/modpathol.2016.63  0.32
2015 Molinaro AM, Wrensch MR, Jenkins RB, Eckel-Passow JE. Statistical considerations on prognostic models for glioma. Neuro-Oncology. PMID 26657835 DOI: 10.1093/neuonc/nov255  0.32
2015 Walsh KM, Codd V, Rice T, Nelson CP, Smirnov IV, McCoy LS, Hansen HM, Elhauge E, Ojha J, Francis SS, Madsen NR, Bracci PM, Pico AR, Molinaro AM, Tihan T, ... ... Jenkins RB, et al. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget. PMID 26646793 DOI: 10.18632/oncotarget.6468  0.32
2015 Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, et al. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. Journal of the National Cancer Institute. 108. PMID 26615020 DOI: 10.1093/jnci/djv369  0.32
2015 Hu LS, Ning S, Eschbacher JM, Gaw N, Dueck AC, Smith KA, Nakaji P, Plasencia J, Ranjbar S, Price SJ, Tran N, Loftus J, Jenkins R, O'Neill BP, Elmquist W, et al. Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma. Plos One. 10: e0141506. PMID 26599106 DOI: 10.1371/journal.pone.0141506  0.32
2015 Walsh KM, de Smith AJ, Hansen HM, Smirnov IV, Gonseth S, Endicott AA, Xiao J, Rice T, Fu CH, McCoy LS, Lachance DH, Eckel-Passow JE, Wiencke JK, Jenkins RB, Wrensch MR, et al. A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution. Cancer Research. PMID 26527286 DOI: 10.1158/0008-5472.CAN-15-1105  0.32
2015 Zreik RT, Meyer RG, Jenkins RB, Norambuena GA, Fritchie KJ. A Rare Pediatric Example of Subcutaneous Extraskeletal Osteosarcoma: A Case Report and Review of the Morphologic Differential Diagnosis. The American Journal of Dermatopathology. PMID 26460626 DOI: 10.1097/DAD.0000000000000458  0.32
2015 Vogelbaum MA, Hu C, Peereboom DM, Macdonald DR, Giannini C, Suh JH, Jenkins RB, Laack NN, Brachman DG, Shrieve DC, Souhami L, Mehta MP. Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. Journal of Neuro-Oncology. PMID 26088460 DOI: 10.1007/s11060-015-1845-7  0.32
2015 Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, ... ... Jenkins RB, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. The New England Journal of Medicine. 372: 2499-508. PMID 26061753 DOI: 10.1056/NEJMoa1407279  0.32
2015 Zhao SG, Jackson WC, Kothari V, Schipper MJ, Erho N, Evans JR, Speers C, Hamstra DA, Niknafs YS, Nguyen PL, Schaeffer EM, Ross AE, Den RB, Klein EA, Jenkins RB, et al. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 25986914 DOI: 10.1038/pcan.2015.22  0.32
2015 Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, ... ... Jenkins RB, et al. Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. European Urology. PMID 25964175 DOI: 10.1016/j.eururo.2015.04.033  0.32
2015 Lobo JM, Dicker AP, Buerki C, Daviconi E, Karnes RJ, Jenkins RB, Patel N, Den RB, Showalter TN. Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis. Plos One. 10: e0116866. PMID 25837660 DOI: 10.1371/journal.pone.0116866  0.32
2015 Wolff AC, Hammond ME, Hicks DG, Allison KH, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, et al. Reply to E.A. Rakha et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1302-4. PMID 25753441 DOI: 10.1200/JCO.2014.59.7559  0.32
2015 Jalali A, Amirian ES, Bainbridge MN, Armstrong GN, Liu Y, Tsavachidis S, Jhangiani SN, Plon SE, Lau CC, Claus EB, Barnholtz-Sloan JS, Il'yasova D, Schildkraut J, Ali-Osman F, Sadetzki S, ... ... Jenkins RB, et al. Targeted sequencing in chromosome 17q linkage region identifies familial glioma candidates in the Gliogene Consortium. Scientific Reports. 5: 8278. PMID 25652157 DOI: 10.1038/srep08278  0.32
2015 Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 701-8. PMID 25605861 DOI: 10.1200/JCO.2014.57.6298  0.32
2015 Bainbridge MN, Armstrong GN, Gramatges MM, Bertuch AA, Jhangiani SN, Doddapaneni H, Lewis L, Tombrello J, Tsavachidis S, Liu Y, Jalali A, Plon SE, Lau CC, Parsons DW, Claus EB, ... ... Jenkins RB, et al. Germline mutations in shelterin complex genes are associated with familial glioma. Journal of the National Cancer Institute. 107: 384. PMID 25482530 DOI: 10.1093/jnci/dju384  0.32
2015 Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. European Urology. 67: 326-33. PMID 24998118 DOI: 10.1016/j.eururo.2014.05.039  0.32
2014 Alshalalfa M, Crisan A, Vergara IA, Ghadessi M, Buerki C, Erho N, Yousefi K, Sierocinski T, Haddad Z, Black PC, Karnes RJ, Jenkins RB, Davicioni E. Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. Bju International. PMID 25762434 DOI: 10.1111/bju.13013  0.32
2014 Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, ... ... Jenkins RB, et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. The Lancet. Oncology. 15: 1469-80. PMID 25456366 DOI: 10.1016/S1470-2045(14)71113-1  0.32
2014 Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M, MacDonald TY, Fontugne J, Erho N, Vergara IA, Ghadessi M, ... ... Jenkins RB, et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nature Communications. 5: 5383. PMID 25415230 DOI: 10.1038/ncomms6383  0.32
2014 Kizilbash SH, Giannini C, Voss JS, Decker PA, Jenkins RB, Hardie J, Laack NN, Parney IF, Uhm JH, Buckner JC. The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. Journal of Neuro-Oncology. 120: 85-93. PMID 24993250 DOI: 10.1007/s11060-014-1520-4  0.32
2014 Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, Kollmeyer T, Kosel ML, Molinaro AM, McCoy LS, Bracci PM, Cabriga BS, Pekmezci M, Zheng S, Wiemels JL, ... ... Jenkins RB, et al. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nature Genetics. 46: 731-5. PMID 24908248 DOI: 10.1038/ng.3004  0.32
2014 Jenkins RB. Editorial commentary on "Analysis of IDH mutation, 1p19q deletion, and PTEN loss delineates prognosis in clinical low-grade gliomas". Neuro-Oncology. 16: 891-2. PMID 24861880 DOI: 10.1093/neuonc/nou100  0.32
2014 Sarkar G, Curran GL, Sarkaria JN, Lowe VJ, Jenkins RB. Peptide carrier-mediated non-covalent delivery of unmodified cisplatin, methotrexate and other agents via intravenous route to the brain. Plos One. 9: e97655. PMID 24847943 DOI: 10.1371/journal.pone.0097655  0.32
2014 Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA, Poliakov A, Vergara IA, Alshalalfa M, Jenkins RB, Davicioni E, Feng FY, Chinnaiyan AM. The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget. 5: 1434-8. PMID 24727738  0.32
2014 Andersson U, Wibom C, Cederquist K, Aradottir S, Borg A, Armstrong GN, Shete S, Lau CC, Bainbridge MN, Claus EB, Barnholtz-Sloan J, Lai R, Il'yasova D, Houlston RS, Schildkraut J, ... ... Jenkins RB, et al. Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. Neuro-Oncology. 16: 1333-40. PMID 24723567 DOI: 10.1093/neuonc/nou052  0.32
2014 Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, Huse JT, Mehta MP, Curran WJ. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 783-90. PMID 24516018 DOI: 10.1200/JCO.2013.49.3726  0.32
2014 Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1288-97. PMID 24398046 DOI: 10.1158/1078-0432.CCR-13-2611  0.32
2014 McCullough AE, Dell'orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Jackisch C, Untch M, Perez EA, Piccart-Gebhart MJ, Viale G. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. Breast Cancer Research and Treatment. 143: 485-92. PMID 24395109 DOI: 10.1007/s10549-013-2827-0  0.32
2014 Meng Y, Sohar I, Sleat DE, Richardson JR, Reuhl KR, Jenkins RB, Sarkar G, Lobel P. Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 547-53. PMID 24394185 DOI: 10.1038/mt.2013.267  0.32
2014 Yoon HH, Sukov WR, Shi Q, Sattler CA, Wiktor AE, Diasio RB, Wu TT, Jenkins RB, Sinicrope FA. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer. 120: 415-24. PMID 24151090 DOI: 10.1002/cncr.28435  0.32
2014 Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson DJ, Triche TJ, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes RJ, et al. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer and Prostatic Diseases. 17: 64-9. PMID 24145624 DOI: 10.1038/pcan.2013.49  0.32
2014 Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Archives of Pathology & Laboratory Medicine. 138: 241-56. PMID 24099077 DOI: 10.5858/arpa.2013-0953-SA  0.32
2013 Won M, Blumenthal DT, Vogelbaum MA, Colman H, Jenkins RB, Chakravarti A, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Dignam J, Atkins JN, Brachman D, Werner-Wasik M, Komaki R, et al. Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: LBA2010. PMID 28136067 DOI: 10.1200/jco.2013.31.18_suppl.lba2010  0.32
2013 Boardman LA, Johnson RA, Viker KB, Hafner KA, Jenkins RB, Riegert-Johnson DL, Smyrk TC, Litzelman K, Seo S, Gangnon RE, Engelman CD, Rider DN, Vanderboom RJ, Thibodeau SN, Petersen GM, et al. Correlation of chromosomal instability, telomere length and telomere maintenance in microsatellite stable rectal cancer: a molecular subclass of rectal cancer. Plos One. 8: e80015. PMID 24278232 DOI: 10.1371/journal.pone.0080015  0.32
2013 Melin B, Jenkins R. Genetics in glioma: Lessons learned from genome-wide association studies Current Opinion in Neurology. 26: 688-692. PMID 24184969 DOI: 10.1097/WCO.0000000000000033  0.32
2013 Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3997-4013. PMID 24101045 DOI: 10.1200/JCO.2013.50.9984  0.32
2013 Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, Jenkins RB, Triche TJ, Malik R, Bedenis R, McGregor N, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nature Genetics. 45: 1392-8. PMID 24076601 DOI: 10.1038/ng.2771  0.32
2013 Dueck AC, Reinholz MM, Geiger XJ, Tenner K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, et al. Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5798-807. PMID 23965903 DOI: 10.1158/1078-0432.CCR-13-0558  0.32
2013 Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, ... ... Jenkins RB, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. Plos One. 8: e66855. PMID 23826159 DOI: 10.1371/journal.pone.0066855  0.32
2013 Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, ... ... Jenkins RB, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. The Journal of Urology. 190: 2047-53. PMID 23770138 DOI: 10.1016/j.juro.2013.06.017  0.32
2013 Walsh KM, Rice T, Decker PA, Kosel ML, Kollmeyer T, Hansen HM, Zheng S, McCoy LS, Bracci PM, Anderson E, Hsuang G, Wiemels JL, Pico AR, Smirnov I, Molinaro AM, ... ... Jenkins RB, et al. Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. Neuro-Oncology. 15: 1041-7. PMID 23733245 DOI: 10.1093/neuonc/not051  0.32
2013 Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Reinholz MM. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2115-22. PMID 23650412 DOI: 10.1200/JCO.2012.42.2642  0.32
2013 Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, Gupta N, Mueller S, James CD, Jenkins R, Sarkaria J, Zhang Z. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes & Development. 27: 985-90. PMID 23603901 DOI: 10.1101/gad.217778.113  0.32
2013 Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M, College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. The Journal of Molecular Diagnostics : Jmd. 15: 415-53. PMID 23562183 DOI: 10.1016/j.jmoldx.2013.03.001  0.32
2013 Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 823-59. PMID 23552377 DOI: 10.1097/JTO.0b013e318290868f  0.32
2013 Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Archives of Pathology & Laboratory Medicine. 137: 828-60. PMID 23551194 DOI: 10.5858/arpa.2012-0720-OA  0.32
2013 Moreno-Aspitia A, Dueck AC, Ghanem-Cañete I, Patel T, Dakhil S, Johnson D, Franco S, Kahanic S, Colon-Otero G, Tenner KS, Rodeheffer R, McCullough AE, Jenkins RB, Palmieri FM, Northfelt D, et al. RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Research and Treatment. 138: 427-35. PMID 23479422 DOI: 10.1007/s10549-013-2469-2  0.32
2013 Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, et al. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Research and Treatment. 138: 99-108. PMID 23420271 DOI: 10.1007/s10549-013-2444-y  0.32
2013 Rice T, Zheng S, Decker PA, Walsh KM, Bracci P, Xiao Y, McCoy LS, Smirnov I, Patoka JS, Hansen HM, Hsuang G, Wiemels JL, Tihan T, Pico AR, Prados MD, ... ... Jenkins RB, et al. Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. Neuro-Oncology. 15: 535-41. PMID 23361564 DOI: 10.1093/neuonc/nos324  0.32
2013 Mansfield AS, Sukov WR, Eckel-Passow JE, Sakai Y, Walsh FJ, Lonzo M, Wiktor AE, Dogan A, Jenkins RB. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer. American Journal of Clinical Pathology. 139: 144-50. PMID 23355198 DOI: 10.1309/AJCP13GJAOJAYJMW  0.32
2013 Sadetzki S, Bruchim R, Oberman B, Armstrong GN, Lau CC, Claus EB, Barnholtz-Sloan JS, Il'yasova D, Schildkraut J, Johansen C, Houlston RS, Shete S, Amos CI, Bernstein JL, Olson SH, ... Jenkins RB, et al. Description of selected characteristics of familial glioma patients - results from the Gliogene Consortium. European Journal of Cancer (Oxford, England : 1990). 49: 1335-45. PMID 23290425 DOI: 10.1016/j.ejca.2012.11.009  0.32
2013 Walsh KM, Anderson E, Hansen HM, Decker PA, Kosel ML, Kollmeyer T, Rice T, Zheng S, Xiao Y, Chang JS, McCoy LS, Bracci PM, Wiemels JL, Pico AR, Smirnov I, ... ... Jenkins RB, et al. Analysis of 60 reported glioma risk SNPs replicates published GWAS findings but fails to replicate associations from published candidate-gene studies. Genetic Epidemiology. 37: 222-8. PMID 23280628 DOI: 10.1002/gepi.21707  0.32
2013 Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 337-43. PMID 23071247 DOI: 10.1200/JCO.2012.43.2674  0.32
2012 Egan KM, Wrensch MR, Jenkins RB. Rare and uncommon genetic variants may hold key to the 'missing heritability' in glioma. Cns Oncology. 1: 109-12. PMID 25057857 DOI: 10.2217/cns.12.19  0.32
2012 Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genetics. 205: 613-21. PMID 23238284 DOI: 10.1016/j.cancergen.2012.10.009  0.32
2012 Jacobs DI, Walsh KM, Wrensch M, Wiencke J, Jenkins R, Houlston RS, Bondy M, Simon M, Sanson M, Gousias K, Schramm J, Labussière M, Di Stefano AL, Wichmann HE, Müller-Nurasyid M, et al. Leveraging ethnic group incidence variation to investigate genetic susceptibility to glioma: a novel candidate SNP approach. Frontiers in Genetics. 3: 203. PMID 23091480 DOI: 10.3389/fgene.2012.00203  0.32
2012 Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3932-8. PMID 22987085 DOI: 10.1200/JCO.2012.43.1890  0.32
2012 Sun X, Vengoechea J, Elston R, Chen Y, Amos CI, Armstrong G, Bernstein JL, Claus E, Davis F, Houlston RS, Il'yasova D, Jenkins RB, Johansen C, Lai R, Lau CC, et al. A variable age of onset segregation model for linkage analysis, with correction for ascertainment, applied to glioma. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 2242-51. PMID 22962404 DOI: 10.1158/1055-9965.EPI-12-0703  0.32
2012 Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe SB, Miller RM, Erho N, Vergara IA, Ghadessi M, Huang Z, Gurel B, Park BH, Davicioni E, Jenkins RB, Platz EA, et al. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proceedings of the National Academy of Sciences of the United States of America. 109: 14977-82. PMID 22927397 DOI: 10.1073/pnas.1203525109  0.32
2012 Jenkins RB, Xiao Y, Sicotte H, Decker PA, Kollmeyer TM, Hansen HM, Kosel ML, Zheng S, Walsh KM, Rice T, Bracci P, McCoy LS, Smirnov I, Patoka JS, Hsuang G, et al. A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nature Genetics. 44: 1122-5. PMID 22922872 DOI: 10.1038/ng.2388  0.32
2012 Rajaraman P, Melin BS, Wang Z, McKean-Cowdin R, Michaud DS, Wang SS, Bondy M, Houlston R, Jenkins RB, Wrensch M, Yeager M, Ahlbom A, Albanes D, Andersson U, Freeman LE, et al. Genome-wide association study of glioma and meta-analysis. Human Genetics. 131: 1877-88. PMID 22886559 DOI: 10.1007/s00439-012-1212-0  0.32
2012 Cen L, Carlson BL, Schroeder MA, Ostrem JL, Kitange GJ, Mladek AC, Fink SR, Decker PA, Wu W, Kim JS, Waldman T, Jenkins RB, Sarkaria JN. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro-Oncology. 14: 870-81. PMID 22711607 DOI: 10.1093/neuonc/nos114  0.32
2012 Liu Y, Melin BS, Rajaraman P, Wang Z, Linet M, Shete S, Amos CI, Lau CC, Scheurer ME, Tsavachidis S, Armstrong GN, Houlston RS, Hosking FJ, Claus EB, Barnholtz-Sloan J, ... ... Jenkins RB, et al. Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma. Human Genetics. 131: 1507-17. PMID 22688887 DOI: 10.1007/s00439-012-1187-x  0.32
2012 Graham RP, Hodge JC, Folpe AL, Oliveira AM, Meyer KJ, Jenkins RB, Sim FH, Sukov WR. A cytogenetic analysis of 2 cases of phosphaturic mesenchymal tumor of mixed connective tissue type. Human Pathology. 43: 1334-8. PMID 22503486 DOI: 10.1016/j.humpath.2011.11.020  0.32
2012 Itsara A, Vissers LE, Steinberg KM, Meyer KJ, Zody MC, Koolen DA, de Ligt J, Cuppen E, Baker C, Lee C, Graves TA, Wilson RK, Jenkins RB, Veltman JA, Eichler EE. Resolving the breakpoints of the 17q21.31 microdeletion syndrome with next-generation sequencing. American Journal of Human Genetics. 90: 599-613. PMID 22482802 DOI: 10.1016/j.ajhg.2012.02.013  0.32
2012 Xiao Y, Decker PA, Rice T, McCoy LS, Smirnov I, Patoka JS, Hansen HM, Wiemels JL, Tihan T, Prados MD, Chang SM, Berger MS, Kosel ML, Fridley BL, Lachance DH, ... ... Jenkins RB, et al. SSBP2 variants are associated with survival in glioblastoma patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3154-62. PMID 22472174 DOI: 10.1158/1078-0432.CCR-11-2778  0.32
2012 Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 546-54. PMID 22252257 DOI: 10.1158/1078-0432.CCR-11-2272  0.32
2012 Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. Journal of the National Cancer Institute. 104: 159-62. PMID 22138096 DOI: 10.1093/jnci/djr490  0.32
2012 Lasho TL, Tefferi A, Pardanani A, Finke CM, Fink SR, Caron AA, Decker PA, Jenkins RB. Differential distribution of CCDC26 glioma-risk alleles in myeloid malignancies with mutant IDH1 compared with their IDH2R140-mutated or IDH-unmutated counterparts. Leukemia. 26: 1406-7. PMID 22116548 DOI: 10.1038/leu.2011.336  0.32
2012 Singhi AD, Cimino-Mathews A, Jenkins RB, Lan F, Fink SR, Nassar H, Vang R, Fetting JH, Hicks J, Sukumar S, De Marzo AM, Argani P. MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 25: 378-87. PMID 22056952 DOI: 10.1038/modpathol.2011.171  0.32
2012 Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, James CD, Jenkins RB, Boni J, Erlichman C, Haluska P. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. Investigational New Drugs. 30: 1934-41. PMID 21881915 DOI: 10.1007/s10637-011-9742-1  0.32
2011 Sarkar G, Curran GL, Mahlum E, Decklever T, Wengenack TM, Blahnik A, Hoesley B, Lowe VJ, Poduslo JF, Jenkins RB. A carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brain. Plos One. 6: e28881. PMID 22216132 DOI: 10.1371/journal.pone.0028881  0.32
2011 Brisbin AG, Asmann YW, Song H, Tsai YY, Aakre JA, Yang P, Jenkins RB, Pharoah P, Schumacher F, Conti DV, Duggan DJ, Jenkins M, Hopper J, Gallinger S, Newcomb P, et al. Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development. Bmc Medical Genetics. 12: 156. PMID 22142333 DOI: 10.1186/1471-2350-12-156  0.32
2011 Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4491-7. PMID 22042958 DOI: 10.1200/JCO.2011.36.7045  0.32
2011 Shete S, Lau CC, Houlston RS, Claus EB, Barnholtz-Sloan J, Lai R, Il'yasova D, Schildkraut J, Sadetzki S, Johansen C, Bernstein JL, Olson SH, Jenkins RB, Yang P, Vick NA, et al. Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the Gliogene Consortium. Cancer Research. 71: 7568-75. PMID 22037877 DOI: 10.1158/0008-5472.CAN-11-0013  0.32
2011 Lachance DH, Yang P, Johnson DR, Decker PA, Kollmeyer TM, McCoy LS, Rice T, Xiao Y, Ali-Osman F, Wang F, Stoddard SM, Sprau DJ, Kosel ML, Wiencke JK, Wiemels JL, ... ... Jenkins RB, et al. Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking. American Journal of Epidemiology. 174: 574-81. PMID 21742680 DOI: 10.1093/aje/kwr124  0.32
2011 Jentoft M, Giannini C, Rossi S, Mota R, Jenkins RB, Rodriguez FJ. Oligodendroglial tumors with marked desmoplasia: clinicopathologic and molecular features of 7 cases. The American Journal of Surgical Pathology. 35: 845-52. PMID 21552114 DOI: 10.1097/PAS.0b013e3182189693  0.32
2011 Jenkins RB, Wrensch MR, Johnson D, Fridley BL, Decker PA, Xiao Y, Kollmeyer TM, Rynearson AL, Fink S, Rice T, McCoy LS, Halder C, Kosel ML, Giannini C, Tihan T, et al. Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genetics. 204: 13-8. PMID 21356187 DOI: 10.1016/j.cancergencyto.2010.10.002  0.32
2011 Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, Ketterling RP, Sukov WR, Kanehira K, Chen B, Geiger XJ, Andorfer CA, McCullough AE, Davidson NE, Martino S, et al. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 651-9. PMID 21245420 DOI: 10.1200/JCO.2010.30.2125  0.32
2011 Jaeckle KA, Decker PA, Ballman KV, Flynn PJ, Giannini C, Scheithauer BW, Jenkins RB, Buckner JC. Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. Journal of Neuro-Oncology. 104: 253-9. PMID 21153680 DOI: 10.1007/s11060-010-0476-2  0.32
2010 Reinholz MM, Eckel-Passow JE, Anderson SK, Asmann YW, Zschunke MA, Oberg AL, McCullough AE, Dueck AC, Chen B, April CS, Wickham-Garcia E, Jenkins RB, Cunningham JM, Jen J, Perez EA, et al. Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform. Bmc Medical Genomics. 3: 60. PMID 21172013 DOI: 10.1186/1755-8794-3-60  0.32
2010 D'Assoro AB, Leontovich A, Amato A, Ayers-Ringler JR, Quatraro C, Hafner K, Jenkins RB, Libra M, Ingle J, Stivala F, Galanis E, Salisbury JL. Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts. International Journal of Oncology. 37: 1167-76. PMID 20878064 DOI: 10.3892/ijo-00000768  0.32
2010 Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling RP, Ingle JN, Lingle WL, Kaufman PA, ... ... Jenkins RB, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4307-15. PMID 20697084 DOI: 10.1200/JCO.2009.26.2154  0.32
2010 Schwartzbaum JA, Xiao Y, Liu Y, Tsavachidis S, Berger MS, Bondy ML, Chang JS, Chang SM, Decker PA, Ding B, Hepworth SJ, Houlston RS, Hosking FJ, Jenkins RB, Kosel ML, et al. Inherited variation in immune genes and pathways and glioblastoma risk. Carcinogenesis. 31: 1770-7. PMID 20668009 DOI: 10.1093/carcin/bgq152  0.32
2010 Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, Whitcomb J, Lingle W, Jenkins RB, Chen B, Larson JS, Tan Y, Sherwood T, Bates M, Perez EA. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. American Journal of Clinical Pathology. 134: 303-11. PMID 20660336 DOI: 10.1309/AJCP3BZY4YAFNTRG  0.32
2010 Gray-McGuire C, Guda K, Adrianto I, Lin CP, Natale L, Potter JD, Newcomb P, Poole EM, Ulrich CM, Lindor N, Goode EL, Fridley BL, Jenkins R, Le Marchand L, Casey G, et al. Confirmation of linkage to and localization of familial colon cancer risk haplotype on chromosome 9q22. Cancer Research. 70: 5409-18. PMID 20551049 DOI: 10.1158/0008-5472.CAN-10-0188  0.32
2010 Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, ... Jenkins RB, et al. Pleiotropic role for MYCN in medulloblastoma. Genes & Development. 24: 1059-72. PMID 20478998 DOI: 10.1101/gad.1907510  0.32
2010 Robertson LB, Armstrong GN, Olver BD, Lloyd AL, Shete S, Lau C, Claus EB, Barnholtz-Sloan J, Lai R, Il'yasova D, Schildkraut J, Bernstein JL, Olson SH, Jenkins RB, Yang P, et al. Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation. Familial Cancer. 9: 413-21. PMID 20455025 DOI: 10.1007/s10689-010-9346-5  0.32
2010 Bender AM, Collier LS, Rodriguez FJ, Tieu C, Larson JD, Halder C, Mahlum E, Kollmeyer TM, Akagi K, Sarkar G, Largaespada DA, Jenkins RB. Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas. Cancer Research. 70: 3557-65. PMID 20388773 DOI: 10.1158/0008-5472.CAN-09-4674  0.32
2010 Kelly JJ, Blough MD, Stechishin OD, Chan JA, Beauchamp D, Perizzolo M, Demetrick DJ, Steele L, Auer RN, Hader WJ, Westgate M, Parney IF, Jenkins R, Cairncross JG, Weiss S. Oligodendroglioma cell lines containing t(1;19)(q10;p10). Neuro-Oncology. 12: 745-55. PMID 20388696 DOI: 10.1093/neuonc/noq031  0.32
2010 Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, ... ... Jenkins RB, et al. A multigene predictor of outcome in glioblastoma. Neuro-Oncology. 12: 49-57. PMID 20150367 DOI: 10.1093/neuonc/nop007  0.32
2010 Wang X, Zamolyi RQ, Zhang H, Pannain VL, Medeiros F, Erickson-Johnson M, Jenkins RB, Oliveira AM. Fusion of HMGA1 to the LPP/TPRG1 intergenic region in a lipoma identified by mapping paraffin-embedded tissues. Cancer Genetics and Cytogenetics. 196: 64-7. PMID 19963137 DOI: 10.1016/j.cancergencyto.2009.09.003  0.32
2010 Wang M, Cairncross G, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Mehta M, Curran W, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International Journal of Radiation Oncology, Biology, Physics. 77: 662-9. PMID 19783377 DOI: 10.1016/j.ijrobp.2009.06.004  0.32
2010 Bender AM, Rodriguez FJ, Sarkar G, Jenkins RB. Tumors of the Nervous System Cancer Cytogenetics. 597-619. DOI: 10.1002/9781118010136.ch19  0.32
2009 Collier LS, Adams DJ, Hackett CS, Bendzick LE, Akagi K, Davies MN, Diers MD, Rodriguez FJ, Bender AM, Tieu C, Matise I, Dupuy AJ, Copeland NG, Jenkins NA, Hodgson JG, ... ... Jenkins RB, et al. Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Research. 69: 8429-37. PMID 19843846 DOI: 10.1158/0008-5472.CAN-09-1760  0.32
2009 Steensma DP, Neiger JD, Porcher JC, Keats JJ, Bergsagel PL, Dennis TR, Knudson RA, Jenkins RB, Santana-Davila R, Kumar R, Ketterling RP. Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. Cancer Research. 69: 7518-23. PMID 19773435 DOI: 10.1158/0008-5472.CAN-09-1428  0.32
2009 Rossi S, Rodriguez F, Dei Tos A, Di Paola F, Bendini M, Jenkins R, Giannini C. Re: Diffuse leptomeningeal glioneuronal tumors: a new entity? Brain Pathology (Zurich, Switzerland). 19: 745; author reply 74. PMID 19744049 DOI: 10.1111/j.1750-3639.2009.00330.x  0.32
2009 Cicek MS, Slager SL, Achenbach SJ, French AJ, Blair HE, Fink SR, Foster NR, Kabat BF, Halling KC, Cunningham JM, Cerhan JR, Jenkins RB, Boardman LA, Petersen GM, Sargent DJ, et al. Functional and clinical significance of variants localized to 8q24 in colon cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 2492-500. PMID 19690179 DOI: 10.1158/1055-9965.EPI-09-0362  0.32
2009 Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, Ballman KV, Berger M, Buckner JC, Chang S, Giannini C, Halder C, Kollmeyer TM, Kosel ML, LaChance DH, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nature Genetics. 41: 905-8. PMID 19578366 DOI: 10.1038/ng.408  0.32
2009 Rossi S, Rodriguez FJ, Mota RA, Dei Tos AP, Di Paola F, Bendini M, Agostini S, Longatti P, Jenkins RB, Giannini C. Primary leptomeningeal oligodendroglioma with documented progression to anaplasia and t(1;19)(q10;p10) in a child. Acta Neuropathologica. 118: 575-7. PMID 19562354 DOI: 10.1007/s00401-009-0565-5  0.32
2009 Drucker KL, Kitange GJ, Kollmeyer TM, Law ME, Passe S, Rynearson AL, Blair H, Soderberg CL, Morlan BW, Ballman KV, Giannini C, Jenkins RB. Characterization and gene expression profiling in glioma cell lines with deletion of chromosome 19 before and after microcell-mediated restoration of normal human chromosome 19. Genes, Chromosomes & Cancer. 48: 854-64. PMID 19544381 DOI: 10.1002/gcc.20688  0.32
2009 Wang X, Hulshizer RL, Erickson-Johnson MR, Flynn HC, Jenkins RB, Lloyd RV, Oliveira AM. Identification of novel HMGA2 fusion sequences in lipoma: evidence that deletion of let-7 miRNA consensus binding site 1 in the HMGA2 3' UTR is not critical for HMGA2 transcriptional upregulation. Genes, Chromosomes & Cancer. 48: 673-8. PMID 19431195 DOI: 10.1002/gcc.20674  0.32
2009 Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, Jenkins RB, Persons DL, Tubbs RR, Hammond ME. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Archives of Pathology & Laboratory Medicine. 133: 611-2. PMID 19391661 DOI: 10.1043/1543-2165-133.4.611  0.32
2009 Sukov WR, Ketterling RP, Lager DJ, Carlson AW, Sinnwell JP, Chow GK, Jenkins RB, Cheville JC. CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma. Human Pathology. 40: 1296-303. PMID 19386349 DOI: 10.1016/j.humpath.2009.01.016  0.32
2009 Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA, Jenkins RB. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. The Lancet. Oncology. 10: 267-77. PMID 19261255 DOI: 10.1016/S1470-2045(09)70063-4  0.32
2009 Rodriguez FJ, Scheithauer BW, Erickson LA, Jenkins RB, Giannini C. Ectopic low-grade adrenocortical carcinoma in the spinal region: immunohistochemical and molecular cytogenetic study of a pediatric case. The American Journal of Surgical Pathology. 33: 142-8. PMID 18941403 DOI: 10.1097/PAS.0b013e318180deda  0.32
2009 Rodriguez FJ, Mota RA, Scheithauer BW, Giannini C, Blair H, New KC, Wu KJ, Dickson DW, Jenkins RB. Interphase cytogenetics for 1p19q and t(1;19)(q10;p10) may distinguish prognostically relevant subgroups in extraventricular neurocytoma. Brain Pathology (Zurich, Switzerland). 19: 623-9. PMID 18710393 DOI: 10.1111/j.1750-3639.2008.00206.x  0.32
2008 Rodriguez FJ, Giannini C, Asmann YW, Sharma MK, Perry A, Tibbetts KM, Jenkins RB, Scheithauer BW, Anant S, Jenkins S, Eberhart CG, Sarkaria JN, Gutmann DH. Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes. Journal of Neuropathology and Experimental Neurology. 67: 1194-204. PMID 19018242 DOI: 10.1097/NEN.0b013e31818fbe1e  0.32
2008 Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM, Mischel P, Yong WH, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5603-9. PMID 18955445 DOI: 10.1200/JCO.2008.18.0612  0.32
2008 Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, Davis BJ, Asmann YW, Klee GG, Ballman KV, Jenkins RB. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. Plos One. 3: e2318. PMID 18846227 DOI: 10.1371/journal.pone.0002318  0.32
2008 Rodriguez FJ, Scheithauer BW, Giannini C, Bryant SC, Jenkins RB. Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. Cancer. 113: 2779-89. PMID 18816605 DOI: 10.1002/cncr.23899  0.32
2008 McCollum AK, TenEyck CJ, Stensgard B, Morlan BW, Ballman KV, Jenkins RB, Toft DO, Erlichman C. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Research. 68: 7419-27. PMID 18794130 DOI: 10.1158/0008-5472.CAN-07-5175  0.32
2008 Macarenco RS, Uphoff TS, Gilmer HF, Jenkins RB, Thibodeau SN, Lewis JE, Molina JR, Yang P, Aubry MC. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 21: 1168-75. PMID 18587327 DOI: 10.1038/modpathol.2008.113  0.32
2008 Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 21: 1156-67. PMID 18567993 DOI: 10.1038/modpathol.2008.111  0.32
2008 Gilbert JA, Goetz MP, Reynolds CA, Ingle JN, Giordano KF, Suman VJ, Blair HE, Jenkins RB, Lingle WL, Reinholz MM, Adjei AA, Ames MM. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Molecular Cancer Therapeutics. 7: 944-51. PMID 18413808 DOI: 10.1158/1535-7163.MCT-07-0570  0.32
2008 Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology (Zurich, Switzerland). 18: 360-9. PMID 18371182 DOI: 10.1111/j.1750-3639.2008.00129.x  0.32
2008 Rodriguez FJ, Scheithauer BW, Perry A, Oliveira AM, Jenkins RB, Oviedo A, Mork SJ, Palmer CA, Burger PC. Ependymal tumors with sarcomatous change ("ependymosarcoma"): a clinicopathologic and molecular cytogenetic study. The American Journal of Surgical Pathology. 32: 699-709. PMID 18347506 DOI: 10.1097/PAS.0b013e318158234e  0.32
2008 Rodriguez FJ, Thibodeau SN, Jenkins RB, Schowalter KV, Caron BL, O'neill BP, James CD, David James C, Passe S, Slezak J, Giannini C. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Applied Immunohistochemistry & Molecular Morphology : Aimm / Official Publication of the Society For Applied Immunohistochemistry. 16: 59-65. PMID 18091318 DOI: 10.1097/PAI.0b013e31802fac2f  0.32
2008 Rodriguez FJ, Thibodeau SN, Jenkins RB, Schowalter KV, Caron BL, O'neill BP, David James C, Passe S, Slezak J, Giannini C. MGMT immunohistochemical expression and promoter methylation in human glioblastoma (Applied Immunohistochemistry and Molecular Morphology (2008) 16, (59-65)) Applied Immunohistochemistry and Molecular Morphology. 16: 307. DOI: 10.1097/PAI.0b013e3181507893  0.32
2007 Highsmith WE, Meyer KJ, Marley VM, Jenkins RB. Conversion Technology for the separation of maternal and paternal copies of any autosomal chromosome in somatic cell hybrids. Current Protocols in Human Genetics / Editorial Board, Jonathan L. Haines ... [Et Al.]. Unit 3.6. PMID 18428411 DOI: 10.1002/0471142905.hg0306s55  0.32
2007 Zhang H, MacDonald WD, Erickson-Johnson M, Wang X, Jenkins RB, Oliveira AM. Cytogenetic and molecular cytogenetic findings of intimal sarcoma Cancer Genetics and Cytogenetics. 179: 146-149. PMID 18036403 DOI: 10.1016/j.cancergencyto.2007.08.013  0.32
2007 Ida CM, Rolig KA, Hulshizer RL, Van Dyke DL, Randolph JL, Jenkins RB, Nascimento AG, Oliveira AM. Myxoinflammatory fibroblastic sarcoma showing t(2;6)(q31;p21.3) as a sole cytogenetic abnormality Cancer Genetics and Cytogenetics. 177: 139-142. PMID 17854670 DOI: 10.1016/j.cancergencyto.2007.05.018  0.32
2007 Mahlum E, Mandal D, Halder C, Maran A, Yaszemski MJ, Jenkins RB, Bolander ME, Sarkar G. Engineering a noncarrier to a highly efficient carrier peptide for noncovalently delivering biologically active proteins into human cells Analytical Biochemistry. 365: 215-221. PMID 17449004 DOI: 10.1016/j.ab.2007.03.020  0.32
2007 Vencio EF, Jenkins RB, Schiller JL, Huynh TVT, Wenger DD, Inwards CY, Oliveira AM. Clonal cytogenetic abnormalities in Erdheim-Chester disease American Journal of Surgical Pathology. 31: 319-321. PMID 17255779 DOI: 10.1097/01.pas.0000213366.33627.a0  0.32
2007 Macarenco RS, Erickson-Johnson M, Wang X, Jenkins RB, Nascimento AG, Oliveira AM. Cytogenetic and molecular cytogenetic findings in dedifferentiated liposarcoma with neural-like whorling pattern and metaplastic bone formation Cancer Genetics and Cytogenetics. 172: 147-150. PMID 17213023 DOI: 10.1016/j.cancergencyto.2006.07.019  0.32
2007 Leenstra JL, Rodriguez FJ, Frechette CM, Giannini C, Stafford SL, Pollock BE, Schild SE, Scheithauer BW, Jenkins RB, Buckner JC, Brown PD. Central neurocytoma: management recommendations based on a 35-year experience. International Journal of Radiation Oncology, Biology, Physics. 67: 1145-54. PMID 17187939 DOI: 10.1016/j.ijrobp.2006.10.018  0.32
2006 Macarenco RS, Erickson-Johnson M, Wang X, Jenkins RB, Nascimento AG, Oliveira AM. Cytogenetic and molecular genetic findings in dedifferentiated liposarcoma with neural-like whorling pattern and metaplastic bone formation Cancer Genetics and Cytogenetics. 171: 126-129. PMID 17116493 DOI: 10.1016/j.cancergencyto.2006.07.009  0.32
2006 Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, Jenkins RB, Bieberich CJ, De Marzo AM. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Research. 66: 10683-90. PMID 17108105 DOI: 10.1158/0008-5472.CAN-06-0963  0.32
2006 Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma Cancer Research. 66: 9852-9861. PMID 17047046 DOI: 10.1158/0008-5472.CAN-06-1796  0.32
2006 Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer S, Zent CS, Call TG, Jelinek DF, Kay NE, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4634-41. PMID 17008705 DOI: 10.1200/JCO.2006.06.9492  0.32
2006 Oblinger JL, Pearl DK, Boardman CL, Saqr H, Prior TW, Scheithauer BW, Jenkins RB, Burger PC, Yates AJ. Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients. Neuropathology and Applied Neurobiology. 32: 410-8. PMID 16866986 DOI: 10.1111/j.1365-2990.2006.00742.x  0.32
2006 Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB. HER2 testing by local, central, and reference laboratories in specimens from the north central cancer treatment group N9831 intergroup adjuvant trial Journal of Clinical Oncology. 24: 3032-3038. PMID 16809727 DOI: 10.1200/JCO.2005.03.4744  0.32
2006 Murillo H, Schmidt LJ, Karter M, Hafner KA, Kondo Y, Ballman KV, Vasmatzis G, Jenkins RB, Tindall DJ. Prostate cancer cells use genetic and epigenetic mechanisms for progression to androgen independence. Genes, Chromosomes & Cancer. 45: 702-16. PMID 16615098 DOI: 10.1002/gcc.20333  0.32
2006 Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC. Current strategies in treatment of oligodendroglioma: Evolution of molecular signatures of response Journal of Clinical Oncology. 24: 1246-1252. PMID 16525179 DOI: 10.1200/JCO.2005.04.9874  0.32
2005 Perez EA, Suman VJ, Rowland KM, Ingle JN, Salim M, Loprinzi CL, Flynn PJ, Mailliard JA, Kardinal CG, Krook JE, Thrower AR, Visscher DW, Jenkins RB. Two concurrent phast II trials of paclitaxel/carboplatin/trastuzumab (weekly of every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252 Clinical Breast Cancer. 6: 425-432. PMID 16381626  0.32
2005 Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, ... ... Jenkins RB, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England Journal of Medicine. 353: 1673-84. PMID 16236738 DOI: 10.1056/NEJMoa052122  0.32
2005 McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M, Burger PC, Louis DN, Giannini C, Fuller G, Passe S, Blair H, Jenkins RB, Yang H, Ledoux A, et al. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 104: 1468-77. PMID 16088966 DOI: 10.1002/cncr.21338  0.32
2005 Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher DW. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining American Journal of Clinical Pathology. 124: 273-281. PMID 16040300 DOI: 10.1309/J9VX-ABUG-KC4Y-07DL  0.32
2005 Mistry SH, Taylor C, Randerson-Moor JA, Harland M, Turner F, Barrett JH, Whitaker L, Jenkins RB, Knowles MA, Bishop JAN, Bishop DT. Prevalence of 9p21 deletions in UK melanoma families Genes Chromosomes and Cancer. 44: 292-300. PMID 16032697 DOI: 10.1002/gcc.20238  0.32
2005 Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5294-304. PMID 15998902 DOI: 10.1200/JCO.2005.23.622  0.32
2005 Law ME, Templeton KL, Kitange G, Smith J, Misra A, Feuerstein BG, Jenkins RB. Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. Cancer Genetics and Cytogenetics. 160: 1-14. PMID 15949564 DOI: 10.1016/j.cancergencyto.2004.11.012  0.32
Show low-probability matches.